US20010002422A1 - (3,4,7,8,9,10-hexahydro-6, 10 -6H-pyridazino [1,2-a] [1,2,] diazepine-1-carboxylic-acid derivatives - Google Patents

(3,4,7,8,9,10-hexahydro-6, 10 -6H-pyridazino [1,2-a] [1,2,] diazepine-1-carboxylic-acid derivatives Download PDF

Info

Publication number
US20010002422A1
US20010002422A1 US09/765,761 US76576101A US2001002422A1 US 20010002422 A1 US20010002422 A1 US 20010002422A1 US 76576101 A US76576101 A US 76576101A US 2001002422 A1 US2001002422 A1 US 2001002422A1
Authority
US
United States
Prior art keywords
carbon atoms
group
compound
hydrogen
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/765,761
Other versions
US6433164B2 (en
Inventor
Francis Brion
Veronique Croco
Patrick Roussel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PASSAGE TO ADVENTURE
Sanofi Aventis France
Original Assignee
Hoechst Marion Roussel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel filed Critical Hoechst Marion Roussel
Priority to US09/765,761 priority Critical patent/US6433164B2/en
Publication of US20010002422A1 publication Critical patent/US20010002422A1/en
Application granted granted Critical
Publication of US6433164B2 publication Critical patent/US6433164B2/en
Assigned to PASSAGE TO ADVENTURE reassignment PASSAGE TO ADVENTURE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: VALLEY DECORATING COMPANY, INC.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic

Definitions

  • novel compounds of the invention are compounds of the formula
  • R is selected from the group consisting of hydrogen, alkyl of 1 to 18 carbon atoms and aryl and aralkyl of up to 18 carbon atoms and the amine is optionally protected.
  • R as alkyl are methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl and tert-butyl and as aryl or aralkyl are benzyl and naphthyl.
  • Preferred compounds of the invention have the formula
  • R 2 is hydrogen and R 1 is selected from the group consisting of
  • R a , R b , R c and R d are individually selected from the group consisting of alkyl of 1 to 18 carbon atoms, aryl and aryl of up to 18 carbon atoms and mono- or polycyclic containing at least one heteroatom and X is selected from the group consisting of hydrogen, alkyl of 1 to 8 carbon atoms and aryl of up to 14 carbon atoms or R 1 and R 2 together with the nitrogen to which they are attached form a mono- or polycyclic with at least one heteroatom.
  • a preferred compound of formula I has the formula
  • R is alkyl of 1 to 8 carbon atoms, especially 1,1-dimethylethyl.
  • the process of the invention for the preparation of a compound of formula I comprises reacting a compound of the formula
  • the starting material has the formula
  • R, R 1 and R 2 have the above definitions and the dehydrogenation agent is a strong base, an oxidizing agent or a sulfur or selenium derivative.
  • the compounds of formula II are racemic (SR+SS) at the level of the 6-member ring and are novel products. They can be prepared by the following process.
  • R is defined as above and the amine is optionally protected comprises reacting a compound of formula I with a reducing agent.
  • the resulting compound has the formula
  • R, R 1 and R 2 are defined as above and the reducing agent is hydrogen in the presence of Raney nickel, palladium on carbon, palladium dihydroxide in the presence of talc, ruthenium on carbon or rhodium in the presence of aluminum, more preferably hydrogen in the presence of Raney nickel.
  • the reaction is effected in the presence of a solvent such as acetic acid, methanol, ethanol, isopropanol, dimethoxyethane, butanone, DMF or acetonitrile.
  • the compounds of formula IIIA are intermediates for the preparation of pharmacological products such as the compounds described in EP Patent No. 84,095 and in J. Chem. Soc. Perkin Trans. 1, (1986), p. 1011. Other products of formula II are useful in a similar process.
  • Stage A 1-(benzyl) 3-(1,1-dimethylethyl)-2-[1,5-dioxo-2-(1,3-dioxo-14-isoindol-2(3H)-yl-5-benzyloxy-pentyl]-tetrahydro-1,3-(2H)-pyridazine dicarboxylate
  • Stage B ⁇ - [[3-[1,1-dimethylethoxy)carbonyl]-tetrahydro-2 (1H) -pyridazinyl]carbonyl]-1,3-dioxo-1H-isoindole-2- (3H) -butanoic acid
  • a mixture of 4.61 g of the product of Stage A and 47 ml of tetrahydrofuran was mixed at 20° C. and the reaction mixture was hydrogenated at ambient temperature, using 400 mg of palladium on carbon as a catalyst. When the reaction was completed, the reaction mixture was filtered and rinsed with THF to obtain 2.76 g of the desired product.
  • Stage C 1,1-dimethylethyl 9-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-octahydro-6,10-dioxo-6H-pyridazino[1,2-a]-1,2-diazepine-1-carboxylate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

A compound of the formula
Figure US20010002422A1-20010531-C00001
wherein R is alkyl or aralkyl of up to 18 carbon atoms, the amine function being optionally protected are used to prepare compounds of the formula
Figure US20010002422A1-20010531-C00002
in which R retains its previous meaning and the amine is optionally protected.

Description

    OBJECTS OF THE INVENTION
  • It is an object of the invention to provide the novel compounds of formula I and a process and intermediates for their preparation. [0001]
  • It is another object of the invention to provide the novel compounds of formula III and a process for their preparation. [0002]
  • These and other objects and advantages of the invention will become obvious from the following detailed description. [0003]
  • THE INVENTION
  • The novel compounds of the invention are compounds of the formula [0004]
    Figure US20010002422A1-20010531-C00003
  • wherein R is selected from the group consisting of hydrogen, alkyl of 1 to 18 carbon atoms and aryl and aralkyl of up to 18 carbon atoms and the amine is optionally protected. [0005]
  • Examples of R as alkyl are methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl and tert-butyl and as aryl or aralkyl are benzyl and naphthyl. [0006]
  • Preferred compounds of the invention have the formula [0007]
    Figure US20010002422A1-20010531-C00004
  • wherein A is defined as above, R[0008] 2 is hydrogen and R1 is selected from the group consisting of
    Figure US20010002422A1-20010531-C00005
  • R[0009] a, Rb, Rc and Rd are individually selected from the group consisting of alkyl of 1 to 18 carbon atoms, aryl and aryl of up to 18 carbon atoms and mono- or polycyclic containing at least one heteroatom and X is selected from the group consisting of hydrogen, alkyl of 1 to 8 carbon atoms and aryl of up to 14 carbon atoms or R1 and R2 together with the nitrogen to which they are attached form a mono- or polycyclic with at least one heteroatom.
  • Examples of cyclic protective groups are [0010]
    Figure US20010002422A1-20010531-C00006
  • A preferred compound of formula I has the formula [0011]
    Figure US20010002422A1-20010531-C00007
  • wherein R is alkyl of 1 to 8 carbon atoms, especially 1,1-dimethylethyl. [0012]
  • The process of the invention for the preparation of a compound of formula I comprises reacting a compound of the formula [0013]
    Figure US20010002422A1-20010531-C00008
  • in racemic form at the 6-member ring and R is as defined and above the amine is protected with a dehydrogenation agent to form the corresponding compound of formula I. [0014]
  • Preferably, the starting material has the formula [0015]
    Figure US20010002422A1-20010531-C00009
  • wherein R, R[0016] 1 and R2 have the above definitions and the dehydrogenation agent is a strong base, an oxidizing agent or a sulfur or selenium derivative.
  • The compounds of formula II are racemic (SR+SS) at the level of the 6-member ring and are novel products. They can be prepared by the following process. [0017]
    Figure US20010002422A1-20010531-C00010
  • Product of Preparation a+ Product of Preparation b [0018]
    Figure US20010002422A1-20010531-C00011
  • The starting compounds of the said process are described in or can be prepared as set forth in J. Chem. Soc. Perkins Trans. 1 (1979), Vol. 6, p. 1451-1454 Chem. Soc. Chem. Comm. (1977), p. 635-36. [0019]
  • The process of the invention for the preparation of a compound of the formula [0020]
    Figure US20010002422A1-20010531-C00012
  • wherein R is defined as above and the amine is optionally protected comprises reacting a compound of formula I with a reducing agent. [0021]
  • Preferably, the resulting compound has the formula [0022]
    Figure US20010002422A1-20010531-C00013
  • wherein R, R[0023] 1 and R2 are defined as above and the reducing agent is hydrogen in the presence of Raney nickel, palladium on carbon, palladium dihydroxide in the presence of talc, ruthenium on carbon or rhodium in the presence of aluminum, more preferably hydrogen in the presence of Raney nickel. The reaction is effected in the presence of a solvent such as acetic acid, methanol, ethanol, isopropanol, dimethoxyethane, butanone, DMF or acetonitrile.
  • The compounds of formula IIIA are intermediates for the preparation of pharmacological products such as the compounds described in EP Patent No. 84,095 and in J. Chem. Soc. Perkin Trans. 1, (1986), p. 1011. Other products of formula II are useful in a similar process. [0024]
  • The products of formula II and IIA in the SR form or the form of a mixture (SR+SS) are novel intermediates as are the compounds of formula III and IIIA with the proviso that R is not hydrogen or tert.-butyl in formula III and in formula IIIA, R is not hydrogen or tert.-butyl when the amine is protected by phthalimido. EP 94,095 describes a compound of formula IIIA when R is tert.-butyl and the amine is phthalimido. [0025]
  • In the following examples, there are described several preferred embodiments to illustrate the invention. However, it is to be understood that the invention is not intended to be limited to the specific embodiments. [0026]
  • PREPARATION 1 1,1-dimethyl-ethyl 9-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-octahydro-6,10-dioxo-6H-pyridazino[1,2-a] [1,2-diazepine-1-carboxylate
  • Preparation a: 1-(benzyl) and 3-(1,1-dimethyl-ethyl) hexahydro-3-(2H)-pyridazinedicarboxylate [0027]
  • J. Chem. Soc. Chem. Comm. (1977) p. 635-636 or J. Chem. Soc. Perkin Trans. (1979) Vol 6. p. 1451-1454. [0028]
  • 920 μl of BF[0029] 3-Et2O and a solution of 18.85 g of terbutyl trichloroacetimidate, 45.5 ml of cyclohexane and 57.5 ml of dichloro methane were introduced at 20° C. into a suspension of 11.50 g of 1,2-benzyl hexahydro-1,3(2H) pyridazinedicarboxylate and 115 ml of dichloromethane. After isolation and purification treatment, the expected product was obtained.
  • Preparation b: benzyl γ-(chlorocarbonyl)-1,3-dioxo-1H-isoindole-2(3H)-butanoate [0030]
  • 30 g of benzyl γ-carboxy-1,3-dioxo-1H-isoindol-(3H) -butanoate (EP 94,095) were introduced, under a nitrogen atmosphere, into 81 ml of terbutylmethylether. The reaction mixture was then cooled to 0°-2° C. and 17 g of phosphorus pentachloride were added. The reaction mixture was allowed to return to ambient temperature and was stirred for 6 hours, concentrated under reduced pressure, taken to 41° C. and the dry extract obtained was entrained using toluene. The product was held at ambient temperature and under a nitrogen atmosphere, then diluted for use in CH[0031] 2Cl2, to obtain a 0.5 M solution of the desired product.
  • Stage A: 1-(benzyl) 3-(1,1-dimethylethyl)-2-[1,5-dioxo-2-(1,3-dioxo-14-isoindol-2(3H)-yl-5-benzyloxy-pentyl]-tetrahydro-1,3-(2H)-pyridazine dicarboxylate [0032]
  • A 0.5 M solution of 52 ml of the product of Preparation b in, methylene chloride was cooled to 0°-1° C. and 5.6 g of the product of Preparation a and 22 ml of dichloromethane were added thereto. The reaction mixture was stirred for 3 hours at 0°+1° C. and 1.77 ml of pyridine and 11 ml of methylene chloride were added. The dichloromethane was evaporated under reduced pressure at 30° C., followed by taking up in ethyl acetate, washing with aqueous solutions of sodium chloride and sodium bicarbonate. Extraction was carried out with ethyl acetate, followed by drying, rinsing and extracting under reduced pressure to obtain the desired product which was chromatographed on silica and eluting with a heptane-ethyl acetate mixture 60-40 to obtain 4.697 g of the desired product melting at ≦35° C. [0033]
  • Stage B: γ- [[3-[1,1-dimethylethoxy)carbonyl]-tetrahydro-2 (1H) -pyridazinyl]carbonyl]-1,3-dioxo-1H-isoindole-2- (3H) -butanoic acid [0034]
  • A mixture of 4.61 g of the product of Stage A and 47 ml of tetrahydrofuran was mixed at 20° C. and the reaction mixture was hydrogenated at ambient temperature, using 400 mg of palladium on carbon as a catalyst. When the reaction was completed, the reaction mixture was filtered and rinsed with THF to obtain 2.76 g of the desired product. [0035]
  • Stage C: 1,1-dimethylethyl 9-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-octahydro-6,10-dioxo-6H-pyridazino[1,2-a]-1,2-diazepine-1-carboxylate [0036]
  • A solution of 0.846 ml of thionyl chloride in 2.6 ml of dichloromethane was added at 0+2° C. to a mixture of 2.6 g of the product of Stage B, 26 ml of methylene chloride and 50 μl of dimethylformamide. The reaction mixture was allowed to return to ambient temperature and was stirred for 6 hours 20 minutes. The isolation and purification operations are carried out to obtain the desired product. [0037]
  • Example 1 1,1-dimethylethyl (9S),9-(1,3-dihydro-1,3-dioxopyridazino[1,2-a]-diazepine-1-carboxylate
  • a) Preparation of LDA [0038]
  • 7.2 ml of butyllithium were added at about −60° over 10 minutes, under a nitrogen atmosphere with stirring to a mixture of 20 ml of THF and 3.2 ml of diisoopropylamine. The temperature was allowed to rise to 0° C., was held for 1 hour at 0° C. and then was returned to −60° C. [0039]
  • b) Preparation of C[0040] 6H5SeBr
  • 0.26 of bromine were added at 10° C. to a solution of 1.88 g of diphenyldiselenium and 6 ml of THF. The reaction mixture was stirred for 1 hour at 20° C. [0041]
  • c) Reaction [0042]
  • A mixture of 3.44 g of 1,2-dimethylethyl (1S-cis) 9-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-octahydro-6,10-dioxo-6H-pyridazino[1,2-a]-1,2-diazepine-1-carboxylate was cooled at −65° C. and the solution of LDA prepared above was added. The reaction mixture was stirred for 10 minutes and the solution of C[0043] 6H5SeBr was added at a temperature of 60°C.±5° C. The temperature was allowed to return to about 0° C. and 4 ml of water, 1.2 of ml of acetic acid and 4 ml of hydrogen peroxide were added. The temperature was, allowed to rise to 10° C. and the reaction mixture was stirred for 1 hour. Then, 40 ml of a 10% aqueous solution of sodium chloride and 80 ml of ethyl acetate were added. The reaction mixture was decanted, washed with a saturated solution of sodium chloride, and/or sodium bicarbonate at 10%, followed by evaporation under reduced pressure. The resultant mixture was chromatographed on silica, eluting with a methylene chloride-isopropyl ether mixture to obtain 1.3 g of the desired product with a specific rotation of αD=+126.5° C.=0.335/MeOH
  • Use: 1,1-dimethylethyl (1S-cis) 9-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-octahydro-6,10-dioxo-6H-pyridazino [1,2-a] [1,2]-diazepine-1-carboxylate [0044]
  • a) Preparation of the Catalyst [0045]
  • A mixture of 0.106 g of Raney nickel (Jansen) and 2 ml of sodium hydroxide was stirred for 2 hours at 60° C. and the nickel was washed with water. One drop of acetic acid was added to the last wash water and the nickel was then washed with ethanol and ethyl acetate. The nickel obtained was kept under reduced pressure. [0046]
  • b) Reduction [0047]
  • 3 ml of ethyl acetate were added to 0.053 g of nickel prepared as previously and 0.0485 g of the product of Example 1 was added to the suspension obtained. The hydrogenation stage took place at ambient temperature, until there was no further absorption of hydrogen. 2 ml of hydrogen were absorbed and the product had a TLC rf=0.27 eluant isopropyl ether/methylene chloride (50-50). [0048]
  • Various modifications of the products and processes of the invention may be made without departing from the spirit or scope thereof and it is to be understood that the invention is intended to be limited only as defined in the appended claims. [0049]

Claims (15)

What we claim is:
1. A compound of the formula
Figure US20010002422A1-20010531-C00014
wherein R is selected from the group consisting of hydrogen, alkyl of 1 to 18 carbon atoms and aryl and aralkyl of up to 18 carbon atoms and the amine is free or protected.
2. A compound of
claim 1
of the formula
Figure US20010002422A1-20010531-C00015
wherein R is defined as in
claim 1
, R2 is hydrogen and R1 is selected from the group consisting of
Figure US20010002422A1-20010531-C00016
Ra, Rb, Rc and Rd are individually selected from the group consisting of alkyl of 1 to 18 carbon atoms, aryl of up to 18 carbon atoms and mono- or polycyclic containing at least one heteroatom and X is selected from the group consisting of hydrogen, alkyl of 1 to 8 carbon atoms and aryl of up to 14 carbon atoms or R1 and R2 together with the nitrogen to which they are attached form a mono- or polycyclic with at least one heteroatom.
3. A compound of
claim 2
wherein R1 and R2 together with the nitrogen to which they are attached form a polycyclic containing at least one heteroatom.
4. A compound of
claim 3
of the formula
Figure US20010002422A1-20010531-C00017
wherein R is alkyl of 1 to 8 carbon atoms.
5. A compound of
claim 1
wherein R is 1,1-dimethyl-ethyl.
6. A compound of
claim 1
which is 1,1-dimethylethyl (9S), 9-(1,3-dihydro-1,3-dioxo-2H- isoindol-2-yl)-3,4,7,8,9,10-hexahydro-6,10-dioxo-6H-pyridazino[1,2-a]-diazepine-1-carboxylate.
7. A process for the preparation of a compound of
claim 1
wherein R has the definition of
claim 1
and the amine is protected comprising reacting a compound of the formula
Figure US20010002422A1-20010531-C00018
wherein R has the definition of
claim 1
and the amine is protected with a dehydrogenation agent.
8. The process of
claim 7
wherein the starting compound has the formula
Figure US20010002422A1-20010531-C00019
wherein R is defined as in
claim 1
, R2 is hydrogen and R1 is selected from the group consisting of
Figure US20010002422A1-20010531-C00020
Ra, Rb, Rc and Rd are individually selected from the group consisting of alkyl of 1 to 18 carbon atoms, aryl of up to 18 carbon atoms and mono- or polycyclic containing at least one heteroatom and X is selected from the group consisting of hydrogen, alkyl of 1 to 8 carbon atoms and aryl of up to 14 carbon atoms or R1 and R2 together with the nitrogen to which they are attached form a mono- or polycyclic with at least one heteroatom.
9. A process of
claim 7
wherein the dehydrogenation agent is selected from the group consisting of a strong base, an oxidizing agent, a sulfur derivative and a selenium derivative.
10. A compound of the formula
Figure US20010002422A1-20010531-C00021
wherein R is defined as in
claim 1
in SR form or in (SR+SS) mixture form.
11. A compound of
claim 10
of the formula
Figure US20010002422A1-20010531-C00022
wherein R is defined as in
claim 1
, R2 is hydrogen and R1 is selected from the group consisting of
Figure US20010002422A1-20010531-C00023
Ra, Rb, Rc, and Rd are individually selected from the group consisting of alkyl of 1 to 18 carbon atoms, aryl of up to 18 carbon atoms and mono- or polycyclic containing at least one heteroatom and X is selected from the group consisting of hydrogen, alkyl of 1 to 8 carbon atoms and aryl of up to 14 carbon atoms or R1 and R2 together with the nitrogen to which they are attached form a mono- or polycyclic with at least one heteroatom.
12. A process for the preparation of a compound of the formula
Figure US20010002422A1-20010531-C00024
wherein R is defined as in
claim 1
and the amine is optionally protected comprising reacting a compound of
claim 1
with a reducing agent.
13. The process of
claim 12
wherein the reducing agent is hydrogen in the presence of Raney nickel.
14. A process for the preparation of a compound of the formula
Figure US20010002422A1-20010531-C00025
wherein R is defined as in
claim 1
, R2 is hydrogen and R1 is selected from the group consisting of
Figure US20010002422A1-20010531-C00026
Ra, Rb, Rc, and Rd are individually selected from the group consisting of alkyl of 1 to 18 carbon atoms, aryl of up to 18 carbon atoms and mono- or polycyclic containing at least one heteroatom and X is selected from the group consisting of hydrogen, alkyl of 1 to 8 carbon atoms and aryl of up to 14 carbon atoms or R1 and R2 together with the nitrogen to which they are attached form a mono- or polycyclic with at least one heteroatom comprising reacting a compound of
claim 2
with a reducing agent.
15. A compound selected from the group consisting of compounds of the formulae
Figure US20010002422A1-20010531-C00027
Figure US20010002422A1-20010531-C00028
wherein R is defined as in
claim 1
, R2 is hydrogen and R1 is selected from the group consisting of
Figure US20010002422A1-20010531-C00029
Ra, Rb, Rc and Rd are individually selected from the group consisting of alkyl of 1 to 18 carbon atoms, aryl of up to 18 carbon atoms and mono- or polycyclic containing at least one heteroatom and X is selected from the group consisting of hydrogen, alkyl of 1 to 8 carbon atoms and aryl of up to 14 carbon atoms of R1 and R2 together with the nitrogen to which they are attached form a mono- or polycyclic with at least one heteroatom with the proviso that R is not hydrogen or tert-butyl and the protected amine is not phthalamido.
US09/765,761 1998-04-27 2001-01-19 (3,4,7,8,9,10-hexahydro-6, 10 -6H-pyridazino [1,2-a] [1,2] diazepine-1-carboxylic-acid derivatives Expired - Lifetime US6433164B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/765,761 US6433164B2 (en) 1998-04-27 2001-01-19 (3,4,7,8,9,10-hexahydro-6, 10 -6H-pyridazino [1,2-a] [1,2] diazepine-1-carboxylic-acid derivatives

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9805242A FR2777888B1 (en) 1998-04-27 1998-04-27 NOVEL DERIVATIVES OF ACID (3,4,7,8,9,10-HEXAHYDRO-6,10- DIOXO-6H-PYRIDAZINO [1,2-A] [1,2] DIAZEPINE-1-CARBOXYLIC, THEIR PROCESS OF PREPARATION AND THEIR APPLICATION TO THE PREPARATION OF MEDICINES
FR9805242 1998-04-27
US09/296,325 US6258947B1 (en) 1998-04-27 1999-04-22 (3,4,7,8,9,10-hexahydro-6,10-dioxo-6H pyridazino[1,2-A] [1,2] diazepine-1-carboxylic acid derivatives
US09/765,761 US6433164B2 (en) 1998-04-27 2001-01-19 (3,4,7,8,9,10-hexahydro-6, 10 -6H-pyridazino [1,2-a] [1,2] diazepine-1-carboxylic-acid derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/296,325 Continuation US6258947B1 (en) 1998-04-27 1999-04-22 (3,4,7,8,9,10-hexahydro-6,10-dioxo-6H pyridazino[1,2-A] [1,2] diazepine-1-carboxylic acid derivatives

Publications (2)

Publication Number Publication Date
US20010002422A1 true US20010002422A1 (en) 2001-05-31
US6433164B2 US6433164B2 (en) 2002-08-13

Family

ID=9525704

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/296,325 Expired - Lifetime US6258947B1 (en) 1998-04-27 1999-04-22 (3,4,7,8,9,10-hexahydro-6,10-dioxo-6H pyridazino[1,2-A] [1,2] diazepine-1-carboxylic acid derivatives
US09/765,761 Expired - Lifetime US6433164B2 (en) 1998-04-27 2001-01-19 (3,4,7,8,9,10-hexahydro-6, 10 -6H-pyridazino [1,2-a] [1,2] diazepine-1-carboxylic-acid derivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/296,325 Expired - Lifetime US6258947B1 (en) 1998-04-27 1999-04-22 (3,4,7,8,9,10-hexahydro-6,10-dioxo-6H pyridazino[1,2-A] [1,2] diazepine-1-carboxylic acid derivatives

Country Status (9)

Country Link
US (2) US6258947B1 (en)
EP (1) EP0955310B1 (en)
JP (1) JP2000001489A (en)
AT (1) ATE279434T1 (en)
DE (1) DE69921011T2 (en)
DK (1) DK0955310T3 (en)
ES (1) ES2229641T3 (en)
FR (1) FR2777888B1 (en)
PT (1) PT955310E (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6201118B1 (en) 1998-08-19 2001-03-13 Vertex Pharmaceuticals Inc. Process for forming an N-acylated, N,N-containing bicyclic ring from piperazic acid or an ester thereof especially useful as an intermediate in the manufacture of a caspase inhibitor
US6177565B1 (en) 1998-08-19 2001-01-23 Vertex Pharmaceuticals Inc. Process for synthesizing piperazic acid
US6451373B1 (en) * 2000-08-04 2002-09-17 Advanced Cardiovascular Systems, Inc. Method of forming a therapeutic coating onto a surface of an implantable prosthesis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
GB2128984B (en) * 1982-05-12 1985-05-22 Hoffmann La Roche Diaza-bicyclic compounds
US5552397A (en) * 1992-05-18 1996-09-03 E. R. Squibb & Sons, Inc. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
EP0570764B1 (en) * 1992-05-18 2001-07-18 F.Hoffmann-La Roche & Co. Aktiengesellschaft Asymmetric hydrogenation

Also Published As

Publication number Publication date
US6433164B2 (en) 2002-08-13
JP2000001489A (en) 2000-01-07
DK0955310T3 (en) 2005-02-14
US6258947B1 (en) 2001-07-10
PT955310E (en) 2005-01-31
ATE279434T1 (en) 2004-10-15
FR2777888A1 (en) 1999-10-29
DE69921011D1 (en) 2004-11-18
EP0955310A1 (en) 1999-11-10
EP0955310B1 (en) 2004-10-13
FR2777888B1 (en) 2004-07-16
ES2229641T3 (en) 2005-04-16
DE69921011T2 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
KR950002885B1 (en) Indole derivatives
IE893483L (en) Methods of synthesizing benign prostatic hypertropic agents¹and their intermediates
CA2216633C (en) Synthesis of bis-indolylmaleimides
US6433164B2 (en) (3,4,7,8,9,10-hexahydro-6, 10 -6H-pyridazino [1,2-a] [1,2] diazepine-1-carboxylic-acid derivatives
JP2001233855A (en) Method for producing indole type compound
US20030130269A1 (en) Derivatives of octahydro-6, 10-dioxo-6H-pyridazino [1,2-a] [1,2] diazepine-1-carboxylic acid, their preparation process and their use in the preparation of therapeutically active compounds
HU214869B (en) Process for producing 11-substituted-20,21-dinoreburnamenin derivatives and pharmaceutical compositions comprising such compounds
CN100366608C (en) New process for preparing 4-aminomethyl-3-alkoxyiminopyrrolidine methanesulfonate
US5734055A (en) Process for preparing N-tert-butyl-2-pyrazinecarboxamide and N-tert-butyl-2-piperazinecarboxamide
US4158012A (en) Steroid synthesis process using mixed anhydride
US20040054230A1 (en) Synthesis of n,n-dimethyl-3-(4-methyl) benzoyl propionamide a key intermediate of zolpidem
WO1996006109A1 (en) An improved process for preparing side chain derivatives of cyclohexapeptidyl lipopeptides
US5380849A (en) Process for optically pure decahydroisoqiunolines
JP2004059446A (en) Alicycic compound and method for producing the same
US20040030150A1 (en) Method for hydrogenating c-c double bonds
US6426417B1 (en) Processes and intermediates useful to make antifolates
JPH05213839A (en) Novel substituted 2,3-diamino acid
JP2003514908A (en) Methods and intermediates directed to tetrahydro- [1,8] -naphthyridine
WO2022160937A1 (en) Industrial preparation method for high-optical-purity rimegepant intermediate
JPH0656843A (en) 5-acyl-4,5,6,7-tetrahydrothieno(3,2-c)pyridine-2-carboxylic acid derivative and its production
SK283809B6 (en) 2-Azabicyclo[2.2.1]heptane derivatives, preparation and application thereof
JPH0632777A (en) Production of 5-chlorooxyindole
JP2001328993A (en) Optically active phosphine compound
MXPA97008995A (en) New derivatives of 2-azabiciclo [2.2.1] heptano, its preparation and its application
EP0080847A2 (en) Improvements in or relating to the synthesis of dioxane analgesics

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: PASSAGE TO ADVENTURE, HAWAII

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VALLEY DECORATING COMPANY, INC.;REEL/FRAME:014128/0194

Effective date: 20030520

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12